中医怎样治疗白癜风Mersana与默克达成ADC研发协议,热点资讯,
2014年6月25日讯 /生物谷BIOON/ --总部位于美国麻省坎布里奇的生物医药公司Mersana Therapeutics公司最近宣布公司已经和德国默克公司达成研究协议共同开发抗体偶联药物（antibody-drug conjugate, ADC）。Mersana公司并未透露具体的合约细节，仅表示这一合约包括了价值7亿9千万美元的预付款和数额不明的里程碑基金。Mersana公司最近已经和Endo公司、武田药业等公司签订合作协议。默克公司官员在评价这一协议时表示，这次与Mersana公司的合作将为公司加强在癌症领域研发实力有重要意义。近年来德国默克公司一直在艰难重组其研发部门以图重现辉煌，但是目前公司的研发工作仍然困难重重。根据协议，Mersana公司将主要负责临床前期的一些研究工作，而默沙东公司将在临床研究过程中接收药物。（生物谷）
详细英文报道：
Mersana Therapeutics has inked another antibody-drug conjugate development pact, this time with the R&D team at Merck KGaA in Germany.
The Cambridge, MA-based biotech reported this morning that Merck KGaA will offer up some antibodies for use in ADCs, in which an antibody homes in on cancer cells to deliver highly toxic and targeted drugs. There were no numbers in the statement, but a spokesperson for the company says that the package includes $792 million in upfront and potential milestone payments. There was no breakout in the upfront, though discovery deals like this are typically heavily back-ended with biobucks.
Mersana has already partnered its Fleximer platform with Endo. Adimab and more recently Takeda, which forged a deal just weeks ago. The 2012 Fierce 15 company has been working with technology developed by Mikhail "Misha" Papisov at Massachusetts General Hospital and was originally seeded by PureTech about a decade ago. The secret sauce behind Mersana"s technology revolves around the use of its linker with a polymer backbone, which Mersana Chief Business Officer Eva Jack says is "highly soluble, so we can add more toxin to our polymer."
At the beginning of the year NEA partner David Mott--the former CEO of MedImmune--took over at Mersana as executive chairman as Nicholas Bacopoulos returned to his role as a board member after a stint as CEO.
Merck KGaA is jumping into a field pioneered by the likes of Seattle Geics and Roche/Genentech. Over the past few years the German pharma company has been struggling to reorganize its R&D division after some notable failures in the clinic. In this deal the company will leave the discovery work to Mersana and then take on clinical development of any drug candidates that make the cut.
Jack says Mersana now has 29 staffers and is also working on its own pipeline as well as more potential partnerships in the ADC field.
"This new collaboration provides an exciting opportunity to expand our oncology drug discovery and development portfolio into the evolving ADC space," said Dr. Andree Blaukat, head of Merck Serono"s Translational Innovation Platform Oncology in Darmstadt, Germany, in a statement. "We have a long-standing commitment to improving oncology care, and we aim to deliver the best benefit possible to patients. Partnering with Mersana allows us to incorporate cutting-edge research and technical excellence to enrich our pipeline."
